Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS)
CNY 29.1
(-2.68%)
CNY 29.1
(-2.68%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 805.08 Million CNY | -90.82% |
| 2022 | 8.76 Billion CNY | -13.78% |
| 2021 | 10.16 Billion CNY | 211.43% |
| 2020 | 3.26 Billion CNY | 788.83% |
| 2019 | 367.37 Million CNY | 28.5% |
| 2018 | 285.89 Million CNY | 27.5% |
| 2017 | 224.23 Million CNY | 23.03% |
| 2016 | 182.25 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 181.74 Million CNY | 14.62% |
| 2024 Q3 | 239.37 Million CNY | 2.56% |
| 2024 Q2 | 233.39 Million CNY | 28.42% |
| 2023 Q2 | 125.49 Million CNY | -66.63% |
| 2023 FY | 805.08 Million CNY | -90.82% |
| 2023 Q1 | 376.04 Million CNY | -58.68% |
| 2023 Q3 | 150.62 Million CNY | 20.02% |
| 2023 Q4 | 158.56 Million CNY | 5.27% |
| 2022 Q2 | 2.36 Billion CNY | -50.17% |
| 2022 FY | 8.76 Billion CNY | -13.78% |
| 2022 Q4 | 910.17 Million CNY | 21.92% |
| 2022 Q3 | 746.51 Million CNY | -68.43% |
| 2022 Q1 | 4.74 Billion CNY | 71.44% |
| 2021 Q1 | 2.23 Billion CNY | 3.29% |
| 2021 Q3 | 1.01 Billion CNY | -75.43% |
| 2021 FY | 10.16 Billion CNY | 211.43% |
| 2021 Q4 | 2.76 Billion CNY | 171.76% |
| 2021 Q2 | 4.14 Billion CNY | 85.44% |
| 2020 Q3 | 272.51 Million CNY | -62.03% |
| 2020 Q1 | 110.36 Million CNY | 4.97% |
| 2020 FY | 3.26 Billion CNY | 788.83% |
| 2020 Q4 | 2.16 Billion CNY | 694.33% |
| 2020 Q2 | 717.78 Million CNY | 550.39% |
| 2019 Q3 | 92.54 Million CNY | 2.36% |
| 2019 FY | 367.37 Million CNY | 28.5% |
| 2019 Q4 | 105.14 Million CNY | 13.61% |
| 2019 Q2 | 90.41 Million CNY | 14.04% |
| 2019 Q1 | 79.27 Million CNY | -1.8% |
| 2018 Q4 | 80.72 Million CNY | 0.0% |
| 2018 FY | 285.89 Million CNY | 27.5% |
| 2017 FY | 224.23 Million CNY | 23.03% |
| 2016 FY | 182.25 Million CNY | 0.0% |